Abstract Library

#4619 Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study

Introduction: Radioligand therapy with lutetium-177 labelled somatostatin receptor (SSTR) agonists (177Lu-DOTATATE or 177Lu-DOTATOC) showed limited response rate and durability. The novel SSTR antagonist DOTA-LM3 labelled with terbium-161, which co-emits conversion and Auger electrons in addition to β- particles, potentially increasing tumour doses and offering a more effective treatment for micro metastases.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Westerbergh F, McDougall L, Christ E, Nicolas G,

Keywords: Radionuclide therapy, PRRT, Auger electrons, Conversion electrons, Terbium-161, radiolabelled somatostatin antagonist, neuroendocrine tumour,

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#4408 Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,

#4299 Defective DNA repair promotes progression of small intestinal neuroendocrine tumours despite a lack of common genomic drivers

Introduction: The tumorigenesis of small intestinal neuroendocrine tumours (siNETs) is not understood, despite being the most common form of small bowel cancer.

Conference:

Presenting Author: Bolduan F

Authors: Bolduan F, Müller-Bötticher N, Debnath O, Zemojtel T, Kunze C,

Keywords: small intestinal neuroendocrine tumour, pathogenetics, defective DNA repair,

#4256 Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors

Introduction: Approximately half of small intestinal neuroendocrine tumors (siNETs) are multifocal, and recent investigations into the genetic architecture of these tumors have found that they are not clonal. Due to the low mutational rate and slow growing nature of these small tumors, the ‘timing’ of the development of individual tumors has not been possible.

Conference:

Presenting Author:

Authors: Webster A, Makinen N, Ecker S, Beck S, Nakakura E,

Keywords: DNA methylation, Epigenetics, Multifocal Ileal Neuroendocrine Tumor, Multifocal Small Instestinal NET, Metabolic Traits,